重组人生长激素治疗儿童生长激素缺乏症和特发性矮小症的安全性分析作者:区远赵 黄诚花 陈秀英来源:《中国实用医药》2017年第13期
【摘要】 目的 重组人生长激素治疗儿童生长激素缺乏症和特发性矮小症的效果。方法 选取儿童生长激素缺乏症和特发性矮小症患儿各35例作为研究对象, 所有患儿均予以重组人生长激素注射液每晚临睡前30 min进行皮下注射, 观察生长激素缺乏症和特发性矮小症患儿各项身体指标。结果 治疗后, 特发性矮小症患儿促甲状腺激素(TSH)、血清胰岛素样生长因子-1(IGF-1)水平分别为(4.87±0.50)U/L、(110.01±2.88)μg/L, 均高于治疗前的(4.43±0.42)U/L、(95.37±2.57)μg/L, 差异有统计学意义(P
【关键词】 重组人生长激素;儿童;生长激素缺乏症;特发性矮小症
DOI:10.14163/j.cnki.11-5547/r.2017.13.046
【Abstract】 Objective To analyze the effect of recombinant human growth hormone in the treatment of growth hormone deficiency and idiopathic short-small syndrome in children. Methods A total of 35 children with growth hormone deficiency and idiopathic short-small syndrome as study subjects all received recombinant human growth hormone injection by subcutaneous injection 30 min before sleeping every night, and observation was made on physical indicators of children with growth hormone deficiency and idiopathic short-small syndrome. Results After treatment, idiopathic short-small syndrome children had higher thyrotropic hormone (TSH), serum insulin-like growth factor-1 (IGF-1) respectively as (4.87±0.50) U/L and (110.01±2.88) μg/L than (4.43±0.42) U/L and (95.37±2.57) μg/L before treatment, and their difference had statistical significance (P
本文来源:https://www.2haoxitong.net/k/doc/56b0cd1f1fb91a37f111f18583d049649a660e37.html
文档为doc格式